JP2013514986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514986A5 JP2013514986A5 JP2012544869A JP2012544869A JP2013514986A5 JP 2013514986 A5 JP2013514986 A5 JP 2013514986A5 JP 2012544869 A JP2012544869 A JP 2012544869A JP 2012544869 A JP2012544869 A JP 2012544869A JP 2013514986 A5 JP2013514986 A5 JP 2013514986A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- dimethoxy
- phenyl
- pharmaceutically acceptable
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2,6-dichloro-3,5-dimethoxy-phenyl Chemical group 0.000 claims 5
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 150000003839 salts Chemical group 0.000 claims 4
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 claims 1
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- DXCUKNQANPLTEJ-UHFFFAOYSA-N PD173074 Chemical compound CC(C)(C)NC(=O)NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C1=CC(OC)=CC(OC)=C1 DXCUKNQANPLTEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims 1
- 229960002475 halometasone Drugs 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28783109P | 2009-12-18 | 2009-12-18 | |
| US61/287,831 | 2009-12-18 | ||
| PCT/US2010/060956 WO2011075620A1 (en) | 2009-12-18 | 2010-12-17 | Method for treating haematological cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013514986A JP2013514986A (ja) | 2013-05-02 |
| JP2013514986A5 true JP2013514986A5 (cg-RX-API-DMAC10.html) | 2014-02-06 |
Family
ID=43569244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544869A Pending JP2013514986A (ja) | 2009-12-18 | 2010-12-17 | 血液癌の処置方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120258940A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2512476A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2013514986A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011075620A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2830626B1 (en) | 2012-03-30 | 2019-01-02 | Novartis AG | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| AU2014287209B2 (en) * | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| US20170196888A1 (en) * | 2014-06-25 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| CA3128084A1 (en) * | 2019-02-14 | 2020-08-20 | Bridgene Biosciences, Inc. | Fgfr inhibitors for the treatment of cancer |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| AU2020272861A1 (en) * | 2019-04-10 | 2021-10-07 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (FGFR2) |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0113757B8 (pt) | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1904065A2 (en) * | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| ME00011A (me) * | 2005-12-21 | 2009-02-10 | Novartis Ag | Derivati pirimidinilaril uree kao fgf inhibitori |
| BRPI0911491A2 (pt) * | 2008-04-29 | 2016-01-05 | Novartis Ag | métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos. |
| CA2728063A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
-
2010
- 2010-12-17 US US13/516,093 patent/US20120258940A1/en not_active Abandoned
- 2010-12-17 EP EP10801746A patent/EP2512476A1/en not_active Withdrawn
- 2010-12-17 WO PCT/US2010/060956 patent/WO2011075620A1/en not_active Ceased
- 2010-12-17 JP JP2012544869A patent/JP2013514986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266894B (en) | Preparation of (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts | |
| HRP20160287T1 (hr) | Antagonisti cgrp receptora | |
| WO2012083017A3 (en) | Controlled release oral dosage forms of poorly soluble drugs and uses thereof | |
| IL231226A (en) | Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases | |
| NZ606246A (en) | Anticancer derivatives, preparation thereof and therapeutic use thereof | |
| BR112014009092A2 (pt) | dispersão sólida | |
| IL203206A (en) | 2-Amino Derivatives, 4-Amido Quinazoline, Drugs Containing and Using Theirs, and Process for Manufacturing | |
| IL205665A (en) | The history of terroiril, the process of preparing them, the drugs containing them and their use in the preparation of drugs | |
| IL222120A (en) | Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| EP2696679A4 (en) | 2'-CYAN SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES | |
| IL209121A (en) | Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases | |
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| JP2012255026A5 (cg-RX-API-DMAC10.html) | ||
| IL209267A (en) | Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug | |
| JP2012236857A5 (cg-RX-API-DMAC10.html) | ||
| IL207684A (en) | Preserved indole history, a method for making these histories, drugs containing these histories, and their use in making drugs | |
| IL198314A (en) | History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment | |
| EP2635260A4 (en) | COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS | |
| EP2717914A4 (en) | DELAYED FORMULATIONS FOR THE ADMINISTRATION OF PROTEINS AND FOR THEIR MANUFACTURE | |
| IL202248A (en) | Aster 4– (3-Methoxy-4-Chloro-Phenyl) Piprazine-1-Il of Acid 3– (Imidazol-2-Il) -Pyrazolo] 4,3– [b Pyridine – 1-Acetic, Methods of preparation and use in preparation of medicinal products | |
| FR2937972B1 (fr) | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
| EP2648697A4 (en) | METHOD FOR THE PRODUCTION OF MINIEMULSIONS AND USE FOR THE RELEASE OF BIOACTIVE ACTIVE SUBSTANCES | |
| WO2008067399A3 (en) | Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution |